Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.72
-6.0%		$1.84
$1.53
▼
$4.34
$79.87M0.2396,813 shs512,676 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$4.61
-3.6%		$4.84
$3.86
▼
$10.08
$309.25M0.4607,959 shs1.17 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$76.51
-0.4%		$77.96
$40.00
▼
$99.50
$294.65M0.97402,527 shs719,508 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$3.19
+0.3%		$4.27
$2.74
▼
$8.59
$304.17M1.681.46 million shs966,996 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-6.01%-3.91%-2.82%+1.78%+0.58%
Immuneering Corporation stock logo
IMRX
Immuneering
-3.56%-8.17%+1.77%+11.89%-34.61%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-0.43%-4.42%-2.26%+12.38%+26.80%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+0.31%-1.24%-1.85%-31.10%-54.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.72
-6.0%		$1.84
$1.53
▼
$4.34
$79.87M0.2396,813 shs512,676 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$4.61
-3.6%		$4.84
$3.86
▼
$10.08
$309.25M0.4607,959 shs1.17 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$76.51
-0.4%		$77.96
$40.00
▼
$99.50
$294.65M0.97402,527 shs719,508 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$3.19
+0.3%		$4.27
$2.74
▼
$8.59
$304.17M1.681.46 million shs966,996 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-6.01%-3.91%-2.82%+1.78%+0.58%
Immuneering Corporation stock logo
IMRX
Immuneering
-3.56%-8.17%+1.77%+11.89%-34.61%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-0.43%-4.42%-2.26%+12.38%+26.80%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+0.31%-1.24%-1.85%-31.10%-54.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.67
Moderate Buy$7.50336.05% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
3.00
Buy$17.50279.61% Upside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.75
Moderate Buy$107.7040.77% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.57
Reduce$3.12-2.19% Downside

Current Analyst Ratings Breakdown

Latest GANX, IMRX, MYGN, and IRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/9/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$6.00 ➝ $3.60
9/4/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/2/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$88.00 ➝ $100.00
9/1/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/1/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Underweight$5.45 ➝ $2.00
8/31/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
8/27/2026
Immuneering Corporation stock logo
IMRX
Immuneering
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/18/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$5.00 ➝ $3.00
8/17/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$90.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,501.22N/AN/A$0.48 per share3.58
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/A$3.38 per shareN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.37$3.80 per share0.84$3.95 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.16M-$0.50N/AN/AN/AN/A-161.59%-118.36%11/11/2026 (Estimated)
Immuneering Corporation stock logo
IMRX
Immuneering
-$56.03M-$1.04N/AN/AN/AN/A-27.15%-25.75%11/11/2026 (Estimated)
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%11/5/2026 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$1.19N/AN/AN/A-13.96%-16.09%-8.10%11/2/2026 (Estimated)

Latest GANX, IMRX, MYGN, and IRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.1380-$0.11+$0.0280-$0.11$0.03 millionN/A
8/5/2026Q2 2026
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.2643-$0.27-$0.0057-$0.27N/AN/A
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
7/30/2026Q2 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.0579-$0.25-$0.1921-$0.46$206.03 million$190.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.02
4.36
4.36
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
19.47
19.47
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.40
2.21
1.98

Institutional Ownership

CompanyInstitutional Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%

Insider Ownership

CompanyInsider Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
4.15%
Immuneering Corporation stock logo
IMRX
Immuneering
14.90%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2043.64 million41.83 millionOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6064.70 million55.06 millionNot Optionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
303.83 million3.69 millionNot Optionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70095.65 million93.83 millionOptionable

Recent News About These Companies

UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating
September 9 at 1:38 PM  |  marketscreener.comM
Myriad Genetics (NASDAQ:MYGN) Earns Neutral Rating from Analysts at UBS Group
September 9 at 10:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-myriad-genetics-nasdaq-mygn-earns-neutral-rating-from-analysts-at-ubs-group-2026-09-09/
Bank of New York Mellon Corp Makes New $1.93 Million Investment in Myriad Genetics, Inc. $MYGN
September 9 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-193-million-investment-in-myriad-genetics-inc-mygn-2026-09-09/
Therapeutics stocks Q2 recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
September 8 at 12:29 PM  |  msn.comhttps://www.msn.com/en-us/money/general/therapeutics-stocks-q2-recap-benchmarking-myriad-genetics-nasdaq-mygn/ar-AA2bNU96
Myriad Genetics se aproxima de mínima histórica após após rebaixamento da Piper Sandler
September 3, 2026  |  br.advfn.comhttps://br.advfn.com/jornal/2026/09/acoes-myriad-genetics-mygn-caem-rebaixamento-piper-sandler
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/myriad-genetics-shares-fall-7-1-after-piper-sandler-downgrade/ar-AA2blBJc
Piper Sandler downgrades Myriad Genetics (MYGN)
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/piper-sandler-downgrades-myriad-genetics-mygn/ar-AA2bqBKX
Bank of America Corp DE Decreases Stock Holdings in Myriad Genetics, Inc. $MYGN
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-decreases-stock-holdings-in-myriad-genetics-inc-mygn-2026-09-02/
Myriad Genetics downgraded at Piper Sandler on structural challenges
September 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4639038-myriad-genetics-stock-downgraded-piper-sandler
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
September 1, 2026  |  barrons.comhttps://www.barrons.com/articles/myriad-genetics-stock-double-downgrade-profitability-9e1653d8
Analyst Cuts Myriad Genetics to Sell, Slashes Price Target to $2 Amid Structural Profitability Concerns
September 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/analyst-cuts-myriad-genetics-to-sell-slashes-price-target-to-2-amid-structural-profitability-concerns-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Man Group plc Takes $5.19 Million Position in Myriad Genetics, Inc. $MYGN
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-takes-519-million-position-in-myriad-genetics-inc-mygn-2026-08-31/
BlackRock Inc. Acquires New Holdings in Myriad Genetics, Inc. $MYGN
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-acquires-new-holdings-in-myriad-genetics-inc-mygn-2026-08-31/
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352088/15459/en/myriad-genetics-to-present-at-2026-wells-fargo-healthcare-conference.html
Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Myriad Genetics, Inc. $MYGN
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-purchases-new-position-in-myriad-genetics-inc-mygn-2026-08-27/
Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN)
August 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MYGN/pressreleases/3593657/piper-sandler-keeps-their-buy-rating-on-myriad-genetics-mygn/
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Reduce" by Brokerages
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/myriad-genetics-inc-nasdaqmygn-given-average-recommendation-of-reduce-by-brokerages-2026-08-24/
Jefferies Sticks to Their Sell Rating for Myriad Genetics (MYGN)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3985569/jefferies-sticks-to-their-sell-rating-for-myriad-genetics-mygn/
Myriad Genetics CFO Benjamin Wheeler Withholds Shares to Cover RSU Tax Liabilities
August 17, 2026  |  kalkinemedia.comK
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260813580758/en/mygn-shareholder-alert-myriad-genetics-inc.-investors-encouraged-to-contact-kirby-mcinerney-llp-about-potential-securities-laws-violations/
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-reduces-stake-in-myriad-genetics-inc-mygn-2026-08-13/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.72 -0.11 (-6.01%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$1.74 +0.02 (+1.22%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$4.61 -0.17 (-3.56%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$4.70 +0.09 (+1.91%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$76.51 -0.33 (-0.43%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$80.50 +3.99 (+5.21%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$3.19 +0.01 (+0.31%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$3.18 0.00 (-0.16%)
As of 09/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas